Jun 09, 2023 / 03:30PM GMT
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity Analyst
All right. Thank you. Good morning. Thank you for joining us on another great session here for Jefferies Healthcare Conference. Very happy to have the CEO of Invivyd, Dave Hering up here with us. We have a nice introduction of presentation of a few slides, tell us a little bit about the story, and I certainly have lots of questions to ask, and we'll have a nice fireside.
David Hering - Invivyd, Inc. - CEO & Director
All right. Thanks, Michael. It's great to be here. Yes, I think just starting for our legal folks, a whole bunch of forward-looking statements. All is posted on our website as well. And one of the things I think I wanted to start with is I get this question frequently about, okay, we're now into year 3 plus of COVID-19. We've got vaccines, we've got oral antivirals. What really is the unmet need? And what are you trying to solve?
And really there's a multitude of patients that we still see have a huge need related to COVID therapeutics and one that is, in particular
Invivyd Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers